Please assess the completion status of the following clinical trial:

Trial Title: F-18-PSMA-1007 Versus F-18-Fluorocholine PET in Patients With Biochemical Recurrence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* male with original diagnosis of prostate carcinoma with prior definitive therapy~* suspicion of recurrence (3 consecutive PSA rises and/or PSA rise by 2.0 ng/mL or more above nadir after radiotherapy or cryotherapy and/or PSA rise by greater than 0.2 ng/mL after prostatectomy)~* life expectancy of 6 months or more as judged by the investigator~* willing and able to undergo all study procedures~* informed consent in writing (dated and signed)~Exclusion Criteria:~* age: less than18 years~* contraindications for F-18-Fluorocholine~* contraindications for any of the ingredients of F-18-PSMA-1007~* close affiliation with the investigational site; e.g. first-degree relative of the investigator~* at the time of enrolment into this study, participating in another therapeutic clinical trial or has completed study participation in another therapeutic clinical trial within 5 days of enrolment into this trial~* having been previously enrolled in this clinical trial~* mental conditions rendering the subject incapable to understand the nature, scope, and consequences of the trial~* being clinically unstable or requiring emergency treatment~* being considered a vulnerable person

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- F-18-PSMA-1007 (Type: EXPERIMENTAL): Patients will receive F-18-PSMA-1007 PET/CT first, followed by F-18-Fluorocholine PET/CT.
- F-18-Fluorocholine (Type: ACTIVE_COMPARATOR): Patients will receive F-18-Fluorocholine PET/CT first, followed by F-18-PSMA-1007 PET/CT.

Based on this trial design, predict the completion outcome and termination type (if applicable).